Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Global Biotech Corp
MONTREAL, Sept. 11, 2013 /PRNewswire/ - Global Biotech Corp. (OTC-GBIQ) (the "Company") is pleased to announce that it has finalized its acquisition of all the intellectual property, process know-how and methodology for the production of Athanol, a green- technology ethanol fuel alternative, from Purthanol International as of today. Further, the Company has acquired purchase orders of $28.5 million USD for the purchase of ethanol or Athanol from Purthanol International, delivery within the ensuing 12 months. This acquisition was consummated for treasury shares from Global valued at $700,000 USD.
About Global Biotech Corp.
Global is a publicly traded company dedicated to investigating and developing natural products for the neutraceutical, pharmaceutical and cosmeceutical industries. It has recently changed its orientation to focus on green-technology fuel production with its acquisition of the Purthanol extraction process. Visit www.globalbiotechcorp.com for more information.
About Purthanol International
Purthanol International is a company focused on efficient and ecologically sound energy production methodologies. As of Q2, Purthanol International began active work on its Purthanol fuel production, to fulfill purchase orders on hand.
Other than statements of historical fact, included herein, all statements are forward-looking and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results may differ materially from Global's expectations and filings made with the securities regulators. The Company does not assume any obligation to update or revise its forward-looking statements. No stock exchange, securities commission or other regulatory authority has approved or disapproved this information.
©2012 PR Newswire. All Rights Reserved.